Vifor Fresenius Medical Care Renal Pharma Ltd

General

Total Cases8
Active Cases--
Patents16
TypeOperating Company
Elite Ratings
--
--
--
--

Ratings

Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
08/10/23
Summons Issued as to Aurobindo Pharma USA, Inc. on 8/10/2023. (jfm) (Entered: 08/10/2023)
08/10/23
Summons Issued as to Aurobindo Pharma USA, Inc. on 8/10/2023. (jfm) (Entered: 08/10/2023)
08/10/23
Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate CSL Limited, Other Affiliate Vifor Pharma AG, Other Affiliate Fresenius Medical Care AG & Co. KGaA, Other Affiliate Vifor Pharma Participations AG, Other Affiliate CSL Vifor Group, Other Affiliate CSL Behring AG, Other Affiliate CSL Behring Holdings Limited, Other Affiliate Behrin (Holdings) Pty Ltd. for Vifor Fresenius Medical Care Renal Pharma France S.A.S., Vifor Fresenius Medical Care Renal Pharma Ltd. filed by Vifor Fresenius Medical Care Renal Pharma France S.A.S., Vifor Fresenius Medical Care Renal Pharma Ltd. (jfm) (Entered: 08/10/2023)
08/10/23
Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate CSL Limited, Other Affiliate Vifor Pharma AG, Other Affiliate Fresenius Medical Care AG & Co. KGaA, Other Affiliate Vifor Pharma Participations AG, Other Affiliate CSL Vifor Group, Other Affiliate CSL Behring AG, Other Affiliate CSL Behring Holdings Limited, Other Affiliate Behrin (Holdings) Pty Ltd. for Vifor Fresenius Medical Care Renal Pharma France S.A.S., Vifor Fresenius Medical Care Renal Pharma Ltd. filed by Vifor Fresenius Medical Care Renal Pharma France S.A.S., Vifor Fresenius Medical Care Renal Pharma Ltd. (jfm) (Entered: 08/10/2023)
08/10/23
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) see attached. (jfm) (Entered: 08/10/2023)
08/10/23
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) see attached. (jfm) (Entered: 08/10/2023)
08/10/23
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Vifor Fresenius Medical Care Renal Pharma Ltd. on July 4, 2023, and Vifor Fresenius Medical Care Renal Pharma France S.A.S. on June 28, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 1/4/2026. (jfm) (Entered: 08/10/2023)
08/10/23
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Vifor Fresenius Medical Care Renal Pharma Ltd. on July 4, 2023, and Vifor Fresenius Medical Care Renal Pharma France S.A.S. on June 28, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 1/4/2026. (jfm) (Entered: 08/10/2023)
08/10/23
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 08/10/2023)
08/10/23
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jfm) (Entered: 08/10/2023)